A Phase 1 interventional study of Sotatercept and Sotatercept Autoinjector in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 4 sites in United States. Open to female participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of the study is to learn what happens to different forms of sotatercept medications in a healthy person's body over time. Researchers want to know if there is a difference in the healthy person's body when different forms of sotatercept medications are given.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key inclusion criteria include but are not limited to the following:
Is assigned female sex at birth and is a participant of nonchildbearing potential (PONCBP) defined as one of the following:
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single subcutaneous high dose of sotatercept administered via syringe.
Biological: Sotatercept
Participants will receive a single subcutaneous high dose of sotatercept administered via autoinjector.
Biological: Sotatercept Autoinjector
Participants will receive a single subcutaneous low dose of sotatercept administered via autoinjector.
Biological: Sotatercept Autoinjector
Subcutaneous Injection
Also known as: MK-7962, ActRIIA-IgG1Fc, ACE-011
Subcutaneous Auto Injection
Also known as: MK-7962, ActRIIA-IgGIFc, ACE-011
Area Under the Concentration-time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Sotatercept at High Dose
Blood samples will be collected to determine the AUC0-inf of sotatercept in plasma.
Time frame: Predose and at designated timepoints (up to approximately 120 days postdose)
Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Sotatercept at High Dose
Blood samples will be collected to determine the AUC0-last of sotatercept in plasma.
Time frame: Predose and at designated timepoints (up to approximately 120 days postdose
Maximum Observed Concentration (Cmax) of Sotatercept at High Dose
Blood samples will be collected to determine the Cmax of sotatercept in plasma.
Time frame: Predose and at designated timepoints (up to approximately 120 days postdose
Time of the Maximum Observed Concentration (Tmax) of Sotatercept High Dose
Blood samples will be collected to determine the Tmax of sotatercept in plasma.
Time frame: Predose and at designated timepoints (up to approximately 120 days postdose
Apparent Terminal Elimination Half-Life (t1/2) of Sotatercept at High Dose
Blood samples will be collected to determine the t1/2 of sotatercept in plasma.
Time frame: Predose and at designated timepoints (up to approximately 120 days postdose
Apparent Total Plasma Clearance (CL/F) of Sotatercept at High Dose
Blood samples will be collected to determine the CL/F of sotatercept in plasma.
Time frame: Predose and at designated timepoints (up to approximately 120 days postdose
Apparent Volume of Distribution During Terminal Elimination Phase (Vz/F) of Sotatercept at High Dose
Blood samples will be collected to determine the Vz/F of sotatercept in plasma.
Time frame: Predose and at designated timepoints (up to approximately 120 days postdose
Cmax of Sotatercept Low Dose
Blood samples will be collected to determine the Cmax of sotatercept in plasma.
Time frame: Predose and at designated timepoints (up to approximately 120 days postdose
Tmax of Sotatercept at Low Dose
Blood samples will be collected to determine the Tmax of sotatercept in plasma.
Time frame: Predose and at designated timepoints (up to approximately 120 days postdose
AUC0-inf of Sotatercept at Low Dose
Blood samples will be collected to determine the AUC0-inf of sotatercept in plasma.
Time frame: Predose and at designated timepoints (up to approximately 120 days postdose
AUC0-last of Sotatercept at Low Dose
Blood samples will be collected to determine the AUC0-last of sotatercept in plasma.
Time frame: Predose and at designated timepoints (up to approximately 120 days postdose
t1/2 of Sotatercept at Low Dose
Blood samples will be collected to determine the t1/2 of sotatercept in plasma.
Time frame: Predose and at designated timepoints (up to approximately 120 days postdose
CL/F of Sotatercept at Low Dose
Blood samples will be collected to determine the CL/F of sotatercept in plasma.
Time frame: Predose and at designated timepoints (up to approximately 120 days postdose
Vz/F of Sotatercept at Low Dose
Blood samples will be collected to determine the Vz/F of sotatercept in plasma.
Time frame: Predose and at designated timepoints (up to approximately 120 days postdose
Number of Participants who Experienced an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 120 days
Number of Participants who Discontinued the Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 120 days
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from May 2025 to primary completion in Nov 2025, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotatercept